Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.
2006
DOI: 10.1124/mi.6.4.6
|View full text |Cite
|
Sign up to set email alerts
|

COX-2 in Inflammation and Resolution

Abstract: Aspirin and the other NSAIDs have popularized the notion of inhibiting prostaglandins as a common anti-inflammatory strategy based on the erroneous premise that all eicosanoids are, within the context of inflammation, generally detrimental. However, our fascination with aspirin and the emergence of COX-2 has shown a more affable side to lipid mediators based on our increasing interest in the endogenous control of acute inflammation and in factors that mediate its resolution. Epilipoxins, for instance, are prod… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
118
1
7

Year Published

2007
2007
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 153 publications
(129 citation statements)
references
References 55 publications
1
118
1
7
Order By: Relevance
“…Their release by phospholipases gives rise to arachidonic acid and lysophosphatidylcholine (Wymann & Schneiter 2008). Arachidonic acid is then enzymatically converted by cyclooxygenases (COX) to PG, prostacyclins and thromboxanes or by lipoxygenase (LOX) enzymes to leukotrienes (Rajakariar et al 2006, Wymann & Schneiter 2008. Lysophosphatidylcholine is in turn enzymatically converted to lysophosphatidic acid (LPA; Fig.…”
Section: Lipid Mediatorsmentioning
confidence: 99%
See 1 more Smart Citation
“…Their release by phospholipases gives rise to arachidonic acid and lysophosphatidylcholine (Wymann & Schneiter 2008). Arachidonic acid is then enzymatically converted by cyclooxygenases (COX) to PG, prostacyclins and thromboxanes or by lipoxygenase (LOX) enzymes to leukotrienes (Rajakariar et al 2006, Wymann & Schneiter 2008. Lysophosphatidylcholine is in turn enzymatically converted to lysophosphatidic acid (LPA; Fig.…”
Section: Lipid Mediatorsmentioning
confidence: 99%
“…2; Mills & Moolenaar 2003, Wymann & Schneiter 2008. For many years the role of PGs in inflammation has been ascertained from studies conducted using nonsteroidal anti-inflammatory drugs (NSAIDs, which function by blocking COX-catalysed synthesis of prostanoids: PGs, prostacyclins and thromboxanes (Vane & Botting 1998); COX-enzyme-specific knock-out mice (Loftin et al 2002, Rajakariar et al 2006). At the onset of the inflammatory response, under the regulation of E 2 and progesterone (Critchley et al 2001), a range of growth factors, prostanoids, cytokines, chemokines and ILs promote the production of inflammatory prostanoids by inducing expression of COX enzymes.…”
Section: Lipid Mediatorsmentioning
confidence: 99%
“…Interestingly, catalase was recently demonstrated to be effective in abrogation of RIBE-induced DDR in human fibroblasts. 22 Moreover, cyclooxygenase-2 signaling, which is essential in mediating cellular inflammatory responses 37 was recently implicated as a crucial mediator of the bystander effect. 38,39 Therefore it is tempting to speculate that the release of reactive species including NO that occurs in inflammation is also a normal response of other cells to stress.…”
Section: Introductionmentioning
confidence: 99%
“…In addition to its well-known role as a pharmaceutical target for anti-inflammatory drugs in inflammatory diseases, COX-2 also exerts versatile biological activities to resolve inflammation (7)(8)(9). At the onset of inflammation, COX-2 has a potent proinflammatory effect, predominantly through the generation of PGE 2 , whereas in the resolution phase, COX-2 is responsible for producing proresolving PGs, such as PGD 2 , 15-deoxy-D 12,14 -PGJ 2 , and PGF 2a (10)(11)(12)(13).…”
mentioning
confidence: 99%